GUBBA PHARMA IN E NEWS

Read More

Dr Reddy’s Labs acquires injectable product portfolio from Eton Pharma

Hyderabad-based Dr Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from US-based Eton Pharmaceuticals.The portfolio includes the Biorphen (phenylephrine hydrocholoride) Injection...

Continue Reading

Read More

Biological E gets WHO nod to be addl facility for production of J&J vaccine

India’s first indigenously developed RBD protein subunit vaccine, Biological E’s Corbevax, is currently being used to inoculate children in the age group of 12 to...

Continue Reading

Read More

Cipla to hike stake in GoApptiv

The drug major on the other day said that it has entered into definitive agreements for further investment of Rs 25.90 crore in digital tech...

Continue Reading

Read More

Cipla to acquire 21% stake in diagnostic company Achira Labs for Rs 25 cr

The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filingPharma major Cipla Ltd the other day said...

Continue Reading

Read More

Easing of IP restrictions on vaccines is welcome. But it will need to be accompanied by technology transfers

Waiver of IP rights will not amount to anything substantial if pharma companies in the Third World do not have the know-how to produce medicines...

Continue Reading

Read More

Pharma major Lupin collaborates with Accenture to enhance its operational efficiency

Additionally, SAP Fiori apps have also helped enhance the user experience for Lupin employees with simple and easy-to-access data models and analytical reports, the company...

Continue Reading

Read More

Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIV

South African Health Products Regulatory Authority (SAHPRA) has approved the sweet-tasting, heat-stable and ‘4-in-1’ fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine,...

Continue Reading

Read More

Dr Reddy’s arm inks pact with US-based Olema Pharmaceuticals

SynopsisAurigene will also be eligible for up to USD 60 million in potential clinical development and regulatory milestones and up to USD 370 million in...

Continue Reading

Read More

GlaxoSmithKline hopes for boost from respiratory virus jab

Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipelineGlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older...

Continue Reading